Buprenorphine

Pear Therapeutics and Spero Health to Expand Access to Prescription Digital Therapeutics for People in Recovery Across Multiple Locations and States

Retrieved on: 
Wednesday, January 4, 2023
Technology, Mobile, Wireless, FDA, Health Technology, Software, Managed Care, Health, Pharmaceutical, General Health, Language isolate, Cognitive behavioral therapy, Food, Therapy, Suicidal ideation, Policy by press release, Substance use disorder, Smartphone, Buprenorphine, Multimedia, Risk, Opioid use disorder, Reset, Reading, Patient, Drug overdose, Population Health Management, OUD, PDT, FDA, Pear, Food and Drug Administration Modernization Act of 1997, SUD, Pharmaceutical industry, Hospital, Birth control, Mobile phone, Medical device

Spero Health, which has implemented reSET and reSET-O at 14 locations in Kentucky, intends to expand access to eligible patients at its 99 locations throughout Indiana, Kentucky, Ohio, Tennessee, West Virginia, and Virginia.

Key Points: 
  • Spero Health, which has implemented reSET and reSET-O at 14 locations in Kentucky, intends to expand access to eligible patients at its 99 locations throughout Indiana, Kentucky, Ohio, Tennessee, West Virginia, and Virginia.
  • The expansion is part of Spero Health’s commitment to increase patient engagement and retention in recovery by offering FDA-authorized innovative treatment options.
  • We believe having access to patient reported data via Pear’s clinician dashboard gives us better insight into patient behaviors.
  • “With more than 40 million Americans living with addiction, we are proud to expand our work with Spero Health to help more patients who are seeking recovery solutions,” said Julia Strandberg, Chief Commercial Officer at Pear Therapeutics.

Pinnacle Treatment Centers expands Ohio substance abuse treatment network with opening of Niles location

Retrieved on: 
Tuesday, January 3, 2023
Professional Services, Health, General Health, State, Local, Women, Pharmaceutical, Men, Other Professional Services, Public Policy, Government, Insurance, Consumer, Education, Case management, Fentanyl, Buprenorphine, Death, Employment, Disease, Patient, Drug overdose, Methadone, Desert Hope Addiction Treatment Center, Angelica, Topical steroid withdrawal, Ohio Department of Health, Housing, Ohio Department of Job and Family Services, Medicaid, Pharmaceutical industry

Pinnacle Treatment Centers, one of the largest methadone providers in the U.S. announced the opening of a new treatment center in Niles.

Key Points: 
  • Pinnacle Treatment Centers, one of the largest methadone providers in the U.S. announced the opening of a new treatment center in Niles.
  • Dedicated to helping adults struggling with substance use and addiction recovery, Niles Treatment Services will provide medication-assisted treatment through medications methadone and buprenorphine (Suboxone) as part of a thorough treatment program which includes individual, group, and family counseling.
  • An often-overlooked aspect of successful recovery is a network of experts equipped with tools to support someone on their journey,” said Jennifer Morgenstern, Pinnacle Treatment Services Regional Director.
  • “We have been reaching Ohioans through our network of treatment centers across every level of care, and we hope that those in need of services know that help is available.” said Brian Thorn, COO of Pinnacle Treatment Centers.

Shatterproof Applauds the Passage of the MATE Act to Expand Addiction Education

Retrieved on: 
Friday, December 23, 2022
Public Policy, Government, White House, Federal Government, Public Policy, General Health, Health, Mental Health, Healthcare Reform, Congressional News, Views, Well, Education, Doctor of Nursing Practice, Addiction, Mental health, Legislation, School, Pain, SUD, Substance-related disorder, American College, Health, Voices, Omnibus Appropriations Act, 2009, SMART Recovery, House, Drug Safety, Organization, Buprenorphine, National Council, Drug Enforcement Administration, Federation, National Safety Council, American Society of Addiction Medicine, Drug, Opioid use disorder, Research, MAT, Patient, Representative, Curriculum, Society, Oxford, OUD, Maintenance, Student, American College of Medical Toxicology, MATE, Congress, Suds, Louisiana House of Representatives, University, Addiction medicine, DEA, Speech disorder, Pharmaceutical industry, Medicine, The 39 Clues

Shatterproof applauds the passage of the Medication Access and Training Expansion (MATE) Act (H.R.

Key Points: 
  • Shatterproof applauds the passage of the Medication Access and Training Expansion (MATE) Act (H.R.
  • Passage of the MAT Act along with the MATE Act will enable better access to life-saving treatment.
  • The MATE Act mainstreams addiction medical education on SUDs across the nation’s medical educational programs.
  • Shatterproof worked closely with the American Society of Addiction Medicine on the passing of the MATE Act.

Telehealth An Effective Way To Treat Opioid-Use Disorder And Increase Access To Care, According To Peer-Reviewed Study From Bicycle Health

Retrieved on: 
Thursday, December 15, 2022
Psychotherapy, Buprenorphine, Diagnosis, Opioid use disorder, Health, FDA, OUD, BMJ, Medicine, AIIMS, India, All India Institute of Medical Sciences, New Delhi, Opioid, Drug, Pharmacy, Research, History, Patient, Pharmaceutical industry, Health insurance, Medical device

A summary of the key outcomes and insights from the research are available online here in Bicycle Health’s resource center for strategic partners.

Key Points: 
  • A summary of the key outcomes and insights from the research are available online here in Bicycle Health’s resource center for strategic partners.
  • This is higher than the industry average, which is 44% at 90 days.
  • Approximately 70% of new Bicycle Health patients are seen by a buprenorphine-waivered provider on the same or next business day as their initial enrollment outreach.
  • It is a collaboration between BMJ and the All India Institute of Medical Sciences (AIIMS).

FDA Accepts Braeburn's New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder

Retrieved on: 
Thursday, December 8, 2022
Mitigation, Topical steroid withdrawal, SC, Urinary tract infection, Food, Opioid use disorder, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, OUD, Patient, Injection, Headache, Nausea, New Drug Application, Buprenorphine, FDA, Insomnia, Braeburn, CIII, Multimedia, Constipation, Safety, REMS, PDUFA, Pharmaceutical industry

PLYMOUTH MEETING, Pa., Dec. 8, 2022 /PRNewswire/ -- Braeburn announces that the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release weekly and monthly injections for subcutaneous (SC) use (CIII) for moderate to severe opioid use disorder was accepted by the U.S. Food and Drug Administration (FDA). The PDUFA action date is set for May 23, 2023. 

Key Points: 
  • PLYMOUTH MEETING, Pa., Dec. 8, 2022 /PRNewswire/ -- Braeburn announces that the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release weekly and monthly injections for subcutaneous (SC) use (CIII) for moderate to severe opioid use disorder was accepted by the U.S. Food and Drug Administration (FDA).
  • If approved, BRIXADI would be used as part of a complete treatment plan that includes counseling and psychosocial support.
  • BRIXADI will be available through a Risk Evaluation and Mitigation Strategy (REMS) program and administered only by healthcare providers in a healthcare setting.
  • Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder.

Pinnacle Treatment Centers Opens Lacey Treatment Services in New Jersey to Provide Opioid Addiction Treatment

Retrieved on: 
Monday, December 5, 2022
Health, Mental Health, Other Health, Pinnacle, Desert Hope Addiction Treatment Center, Topical steroid withdrawal, Housing, United States drug overdose death rates and totals over time, Garden State, Suite, Opioid use disorder, Garden, Hospital, Health, Patient, Employment, Knowledge, Buprenorphine, FDA, Case management, Woman, Mental health, Medicaid, Methadone, Multimedia, Passages Malibu, MAT, Education, Heroin, Opioid, Chief

Pinnacle Treatment Centers , a leader in providing accessible, affordable care for people seeking treatment for opioid use disorder, has opened Lacey Treatment Services in New Jersey.

Key Points: 
  • Pinnacle Treatment Centers , a leader in providing accessible, affordable care for people seeking treatment for opioid use disorder, has opened Lacey Treatment Services in New Jersey.
  • Medicaid-friendly, Lacey Treatment Services will offer medication-assisted treatment (MAT) for adult men and women, including FDA-approved medicines such as methadone and buprenorphine, which curb withdrawal symptoms from heroin and opioid addiction; prevent relapse; and help ease the physical discomfort that accompanies opioid recovery.
  • Lacey Treatment Services treatment team is comprised of seasoned doctors, registered nurses, and credentialed clinical therapists who have all worked in medication-assisted treatment and bring a wealth of knowledge and experience to the team.
  • Pinnacles 11 addiction treatment centers in New Jersey include:
    Headquartered in Mount Laurel, New Jersey, Pinnacle Treatment Centers is a recognized leader in comprehensive drug and alcohol addiction treatment serving more than 35,000 patients daily in California, Georgia, Indiana, Kentucky, North Carolina, New Jersey, Ohio, Pennsylvania, and Virginia.

Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook

Retrieved on: 
Wednesday, December 7, 2022
Speech disorder, Substance-related disorder, Person, NR, Conditional sentence, Environment, Risk, OHS, OUD, Patient, Communication, Science, BMAT, Annual report, Research, SUD, Buprenorphine, LON, EST, Risperidone, Government, EGM, COVID-19, Growth, Trial of the century, Multimedia, Capital market, RSVP, SG, Acquisition, Management, Bank, Security (finance), Health insurance, Marketing, Risk management, Indivior, Shareholder

SLOUGH, England and RICHMOND, Va., Dec. 7, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) willhold a Capital Markets Day today in New York City.

Key Points: 
  • SLOUGH, England and RICHMOND, Va., Dec. 7, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) willhold a Capital Markets Day today in New York City.
  • The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team and will detail the Company's strategic growth plans and roadmap for delivering long-term shareholder value.
  • Within this outlook, which is based on its current business portfolio, Indivior also expects a return to NR growth in the Rest of the World driven by new products SUBLOCADE (SUBUTEXPR) and SUBOXONE(buprenorphine/naloxone) Film.
  • Indivior expects to achieve significant operating margin expansion over the medium-term driven by an improving gross margin and focused management of operating expenses.

Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook

Retrieved on: 
Wednesday, December 7, 2022
Speech disorder, Substance-related disorder, Person, NR, Conditional sentence, Environment, Risk, OHS, OUD, Patient, Communication, Science, BMAT, Annual report, Research, SUD, Buprenorphine, LON, EST, Risperidone, Government, EGM, COVID-19, Growth, Trial of the century, Capital market, RSVP, SG, Acquisition, Management, Bank, Security (finance), Health insurance, Risk management, Indivior, Shareholder

SLOUGH, England and RICHMOND, Va., Dec. 7, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) willhold a Capital Markets Day today in New York City.

Key Points: 
  • SLOUGH, England and RICHMOND, Va., Dec. 7, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) willhold a Capital Markets Day today in New York City.
  • The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team and will detail the Company's strategic growth plans and roadmap for delivering long-term shareholder value.
  • Within this outlook, which is based on its current business portfolio, Indivior also expects a return to NR growth in the Rest of the World driven by new products SUBLOCADE (SUBUTEXPR) and SUBOXONE(buprenorphine/naloxone) Film.
  • Indivior expects to achieve significant operating margin expansion over the medium-term driven by an improving gross margin and focused management of operating expenses.

NASADAD and AATOD Release New Information about Patients Being Treated in Opioid Treatment Programs (OTPs)

Retrieved on: 
Monday, December 5, 2022
Opioid, Substance Abuse and Mental Health Services Administration, Opioid use disorder, ORN, American Association of Clinical Endocrinologists, National Association, State Alcohol and Tobacco Company of Iceland, Partnership, Patient, Mouding County, Treatment, Naltrexone, SAMHSA, Buprenorphine, Consultant, Methadone, Directory, Pharmaceutical industry, Substance Abuse, OTP

DC and NEW YORK, Dec. 5, 2022 /PRNewswire-PRWeb/ -- In order to capture current patient census data for people being treated for opioid use disorder in OTPs, the American Association for the Treatment of Opioid Dependence (AATOD) in partnership with the National Association of State Alcohol and Drug Abuse Directors (NASADAD), developed a census survey of all patients enrolled in treatment as of January 1, 2021, in Substance Abuse and Mental Health Service Administration (SAMHSA) certified OTPs in the United States (U.S.). The project was supported by the SAMHSA-funded Opioid Response Network (ORN).

Key Points: 
  • Of the 512,224 patients in OTPs who reported using MOUDs, 476,763 reported using methadone, 33,473 reported buprenorphine, and the remaining 1,988 reported using naltrexone.
  • Through this census, AATOD and NASADAD have captured crucial and actionable data to better understand treatment demand and demand for specific medications in OTPs.
  • ORN provides no costs education, training and consultation to enhance efforts addressing the opioid and stimulant use disorder crisis.
  • ORN has representation across the country to help others in applying locally relevant, evidence-based practices across harm reduction, prevention, treatment and recovery.

Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure's First Clinical Pharmacokinetic Study for EMPLI03

Retrieved on: 
Tuesday, November 29, 2022
Quotient, Doctor of Philosophy, Science, PK, Buprenorphine, Pain, Partnership, Chronic pain, Patient, Drug development, GMP, Pharmaceutical industry

The partnership will see Quotient Sciences support the GMP manufactureand first clinical pharmacokinetic (PK) study for EMPLI03 using itsunique Translational Pharmaceutics platform.

Key Points: 
  • The partnership will see Quotient Sciences support the GMP manufactureand first clinical pharmacokinetic (PK) study for EMPLI03 using itsunique Translational Pharmaceutics platform.
  • Quotient Sciences' integrated Translational Pharmaceutics platform has been used to establish the GMP manufacturing process for EMPLI03 and to perform the first clinical PK study.
  • Quotient Sciences introduced its Translational Pharmaceutics platform in 2008 as a fully integrated drug development and clinical testing platform.
  • Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway.